Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Gln-AMS (TFA) | 99.9% | 588.47 | 25 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor that inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. It is provided as a solid, white to off-white in appearance, and is stable under recommended storage conditions, making it suitable for laboratory research in metabolic enzyme, protease, anti-infection, and bacterial studies.
- Inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Available in various quantities for research needs.
- Stable under recommended storage conditions.
- Suitable for in vitro and in vivo dissolution protocols.
Medchemexpress LLC ACV Tripeptide TFA | 477.45 | 25 MG
ACV Tripeptide TFA is a tripeptide that serves as the initial dedicated intermediate in the biosynthetic pathway leading to penicillin and cephalosporin classes of β-lactam natural products in bacteria and fungi. It is nonribosomally synthesized by the ACV synthetase (ACVS) enzyme, encoded by the 11 kb *pchAB* gene, and can be used for the biosynthesis of β-lactam antibiotics. This tripeptide contains the unusual amino acid α-aminoadipic acid (α-AAA), along with L-cysteine and D-valine.
- Tripeptide
- Initial intermediate in β-lactam biosynthesis
- Synthesized by ACV synthetase (ACVS) enzyme
- Contains α-aminoadipic acid (α-AAA), L-cysteine, and D-valine
- Molecular weight: 477.45
- Formula: C16H26F3N3O8S
- Appearance: Solid
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 (free base) | 1 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist that significantly enhances the activation and proliferation of T cells. It inhibits the migration and metastasis and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling. This compound reduces the expression of MCAM and N-cadherin, making it suitable for studies on acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Vasoactive intestinal polypeptide (VIP receptor) antagonist
- Enhances T cell activation and proliferation
- Inhibits migration and metastasis of melanoma cells
- Induces apoptosis in melanoma tumor cells
- Inhibits VIP-VPAC2 signaling
- Reduces MCAM and N-cadherin expression
- Useful for acute myeloid leukemia (AML) research
- Useful for uveal melanoma (UVM) research
![Medchemexpress LLC [D-Lys6]-LH-RH TFA | 1253.41 (free base) | 50 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-250.jpg)
Medchemexpress LLC [D-Lys6]-LH-RH TFA | 1253.41 (free base) | 50 MG
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue that acts as a GnRH receptor agonist. It is used in research, including studies on the inhibition of growth of experimental prostate cancer.
- Luteinizing-hormone-releasing hormone (LHRH) analogue
- Acts as a GnRH receptor agonist
- Used in research, including studies on the inhibition of growth of experimental prostate cancer
Medchemexpress LLC F9170 (TFA) | >98% | 2097.33 | 1 MG
F9170 (trifluoroacetate salt) is an antiviral peptide that corresponds to amino acids 789-803 of the HIV-1 envelope glycoprotein. This product is identified as a laboratory chemical for the manufacture of substances and is strictly for research use only. It must be handled by suitably qualified and experienced scientists in appropriately equipped and authorized facilities.
- Antiviral peptide.
- Corresponds to amino acids 789-803 of the HIV-1 envelope glycoprotein.
- Intended for research use only.
- Suitable for laboratory chemical applications.
- Recommended for handling by experienced personnel.
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 | 100 UG
Clovibactin TFA is the TFA salt form of Clovibactin. It is an antibiotic effective against drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inhibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors.
- Effective against drug-resistant bacterial pathogens
- Exhibits no detectable resistance
- Inhibits cell wall synthesis
- Targets pyrophosphate of peptidoglycan precursors
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Sigma Aldrich Fine Chemicals Biosciences Trifluoroacetic acid 99 fo500G
TRIFLUOROACETIC Trifluoroacetic acid 99 fo500G
Medchemexpress LLC PBX-7011 TFA | 98.6% | 561.46 | 5 MG
PBX-7011 TFA is a derivative of camptothecin. It inhibits expressions of the cancer-related survival genes DDX5, Survivin, Mcl-1, and XIAP in FaDu cells, degrades DDX5 proteins, and exhibits anticancer activity.
- Inhibits expressions of cancer-related survival genes DDX5, Survivin, Mcl-1, and XIAP in FaDu cells.
- Degrades DDX5 proteins.
- Exhibits anticancer activity.
![Medchemexpress LLC Coenzyme A S-[2-[[(5S)-5-(acetylamino)-6-amino-6-oxohexyl]amino]-2-oxoethyl] trifluoroacetic acid | 00-00-0 | 98.5% | C33H54F3N10O21P3S | 10MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000261718.png-250.jpg)
Medchemexpress LLC Coenzyme A S-[2-[[(5S)-5-(acetylamino)-6-amino-6-oxohexyl]amino]-2-oxoethyl] trifluoroacetic acid | 00-00-0 | 98.5% | C33H54F3N10O21P3S | 10MG
Lys-CoA TFA (Lys-coenzyme A) is a selective inhibitor of the p300 histone acetyltransferase used as a biochemical tool to study p300-mediated acetylation and transcriptional regulation. It exhibits nanomolar potency against p300 and marked selectivity over related acetyltransferases, and is supplied as a high-purity solid for laboratory research.
- Selective p300 HAT inhibitor with p300 IC50 50-500 nM
- Greater than 100-fold selectivity over PCAF
- High purity (98.5%) for research applications
- Solid, white to off-white physical form
- Recommended sealed storage at -20°C; in solvent store at -80°C for long-term
eMolecules 76-05-1 | Trifluoroacetic acid | Chem-Impex | MFCD00004169 | 114.023 | C2HF3O2 | 99.000 | OC(=O)C(F)(F)F | 1kg | 272384819
Trifluoroacetic acid | Chem-Impex | 76-05-1 | MFCD00004169 | 114.023 | C2HF3O2 | 99.000 | OC(=O)C(F)(F)F | 1kg | 272384819
Medchemexpress LLC CMD178 TFA | 99.7% | 964.05 | 5 MG
CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling. It also acts as an inhibitor of STAT5 and inhibits Treg cells development.
- Reduces expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling
- Inhibits STAT5
- Inhibits Treg cells development
Medchemexpress LLC Ss47 Tfa | 00-00-0 | 99.9% | 1067.09 | C51H57F3N6O14S | 5 MG
SS47 TFA is a PROTAC-based HPK1 degrader supplied as the trifluoroacetic acid salt for research use. It promotes proteasome-mediated degradation of HPK1 and is used in immuno-oncology and CAR-T cell studies.
- Research reagent for HPK1 degradation and immuno-oncology studies.
- Contains an alkyne moiety compatible with copper-catalyzed azide-alkyne cycloaddition.
- Purity 99.88%.
- Chemical formula C51H57F3N6O14S; molecular weight 1067.09.
- Soluble in DMSO at 100 mg/mL; ultrasonic assistance recommended.
- Store protected from light under nitrogen; in solvent: -80°C (6 months), -20°C (1 month).
- Available in small research pack sizes such as 1 mg, 5 mg, and 10 mg.
Medchemexpress LLC Adrixetinib TFA | C27H25F6N5O7 | 25 MG
Adrixetinib TFA is an Axl/Mer/CSF1R inhibitor. This product is supplied as an off-white to light yellow solid, with a purity of 99.82% as determined by HPLC.
- Axl/Mer/CSF1R inhibitor
- High purity (99.82% by HPLC)
- Off-white to light yellow solid appearance
Medchemexpress LLC Ms15 TFA | C66H80F3N11O7S | 5 MG
MS15 TFA is a potent and selective AKT PROTAC degrader for research use only. It effectively inhibits AKT1, AKT2, and AKT3 activities, demonstrating bioavailability in mice through intraperitoneal administration.
- Potent and selective AKT PROTAC degrader
- Inhibits AKT1, -2, and -3 activities
- IC50 values: 798 nM (AKT-1), 90 nM (AKT-2), 544 nM (AKT-3)
- Bioavailable in mice via intraperitoneal administration
- Purity of 99.82%